1. Multidisciplinary Management in Non-Small Cell Lung Cancer (NSCLC)

3. This program will include data that were presented in abstract form
This program will include data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

4. Patient Case: Initial Information

5. Evidence for Lung Cancer Screening: NLST

6. Evidence for Lung Cancer Screening: NELSON

7. Patient Case: PET/CT

8. PET Images of Lung Nodule

9. Patient Case: Biopsy

10. Best Approach to Biopsy

11. Bone Biopsies

12. Pleural Effusions

13. Patient Case: Tissue Collection and Pathology

14. Pathology Results

15. Pathology Results: Basic Routine Histology

16. Testing for Predictive Biomarkers

17. Inadequate Samples

18. Liquid (Blood-Based) Biopsy

19. Patient Case: PD-L1 Results

20. Average Turnaround Times

21. Patient Case: EGFR Results

22. Patient Case: First-Line EGFR TKI

23. Osimertinib

24. FLAURA Trial: Study Design

25. FLAURA Trial: PFS and OS

26. Patient Case: Progression

27. Patient Case: Resistance

28. FLAURA Trial: Acquired Resistance Mechanisms With Comparator EGFR TKI

29. FLAURA Trial: Acquired Resistance Mechanisms With Osimertinib

30. Other Approaches to Osimertinib-Resistant Patients

31. What About Locally Advanced NSCLC?

32. Surgical Resection and Adjuvant Chemotherapy?

33. Relevant Ongoing Trials

34. Abbreviations

35. Abbreviations (cont)